跳至主要内容
临床试验/NCT01996111
NCT01996111终止不适用

A Prospective, Randomized, Controlled, Blinded, Comparative Study of Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar Fasciitis

MiMedx Group, Inc.2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2013年9月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
14
试验地点
2
主要终点
Reduction of inflammation as measured by AOFAS Hindfoot scores

研究概览

简要总结

This is a prospective, controlled, randomized, blinded and comparative, single-center clinical trial comparing the improvement of patients with recalcitrant plantar fasciitis symptoms that have received standard of care versus treatment with differing amounts of injectable dehydrated human amnion/chorion membrane micrografts(dHACM).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • At least 18 years old.
  • Both male and female patients will be selected.
  • Plantar fasciitis has been treated with conservative usual care for at least 8 weeks, including at least three of the following modalities
  • Rest, Ice, Compression, Elevation (RICE)
  • Corticosteroid injection
  • Stretching exercises
  • Non-steroidal Anti-Inflammatory Drugs (NSAIDs)
  • Orthotics
  • Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers, or abstinence).
  • Patient understands and is willing to participate in the clinical study and can comply with weekly visits and the follow-up regimen.
  • Patient has read and signed the IRB/IEC approved Informed Consent Form before screening procedures are undertaken.
  • Exclusion Criteria
  • Prior surgery at the site.
  • Site that exhibits clinical signs and symptoms of infection.
  • History of chronic plantar fasciitis of more than twelve months.
  • Evidence of significant neurological disease of the feet.
  • Non-ambulatory patients.
  • The presence of comorbidities that can be confused with or can exacerbate the condition including:
  • Calcaneal stress fracture
  • Nerve entrapment syndrome (Baxter's Nerve Entrapment or Tarsal Tunnel Syndrome)
  • Plantar fascial rupture
  • Systemic disorders associated with enthesiopathy (such as Gout, Reiter's syndrome, rheumatoid arthritis, etc.)
  • Achilles tendonitis
  • Fat pad atrophy
  • Fibromyalgia
  • Diabetics with neuropathy
  • Patients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the study.
  • Patients on any investigational drug(s) or therapeutic device(s) within 30 days preceding screening.
  • History of radiation therapy at the site.
  • Known history of having Acquired Immunodeficiency Syndrome (AIDS) or HIV.
  • Study foot has been previously treated with tissue engineered materials within the last 30 days.
  • Patients who are unable to understand the aims and objectives of the trial.
  • Presence of any condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.
  • Pregnant or breast feeding. No pregnancy within the past 6 months.
  • Allergy to Gentamicin and/or Streptomycin.

排除标准

  • 未提供

结局指标

主要结局

Reduction of inflammation as measured by AOFAS Hindfoot scores

时间窗: 8 Weeks

The primary objective of this study is to compare the efficacy of the different treatment amounts in reduction of inflammation as measured by AOFAS Hindfoot scores.

次要结局

  • Return to normal activities more quickly than with standard of care(8 Weeks)
  • Pain as measured by 0-10 Numeric Rating Scale(12 weeks)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验